Randomised controlled group trials are the gold standard in clinical research and provide information about the average effect of a treatment in a target population. Such information, however, cannot necessarily be transferred to a single patient because finding a significant effect of treatment does not mean that all the study subjects responded. Besides, in real life clinicians are often confronted with vague symptoms and poorly defined diseases; this is a different case from the strict criteria used in scientific studies. In an attempt to adapt the general knowledge about a new treatment to a particular patient the clinician tries out drugs. Such an uncontrolled trial and error approach is, however, often biased towards a false positive effect as most disorders are self limiting, the placebo effect may be appreciable, and the patient is eager to please the doctor. All these aspects tend to contribute to the myth that treatment with drugs is a prerequisite for regaining health.
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Controlled trials in individual patients (n of 1 trials) have a long tradition in behavioural medicine' and have recently attracted attention in clinical medicine. Such trials may improve the certainty of a treatment decision in an individual patient, and a series of such trials may permit more general inferences to be drawn about a treatment.
Method of study
The main principle in the n of 1 trial is that the patient serves as his or her own control in a study of In an attempt to indentify individual responders to H2 receptor antagonists in non-ulcer dyspepsia I and my colleagues devised a multicrossover model in which the effect of cimetidine was compared with that of placebo. We used treatment periods of one, two, and four days. The crossover model was later revised to improve its validity,1 and the current version requires that six tablets of cimetidine (400 mg or 800 mg) and six tablets of placebo are given in a double blind, randomised order. To adjust for instability in dyspepsia and to avoid possible carryover effects, the tablets are taken only when needed for relief of symptoms. The patient measures the alleviating effect of each tablet and an individual p value or confidence interval is determined. This method showed a beneficial effect of cimetidine among individual patients with reflux-like non-ulcer dyspepsia and confirmed the drug's effect on the symptoms of oesophagitis and peptic ulcer disease. ' In two earlier studies of the effect of cimetidine in non-ulcer dyspepsia we combined the results from many of n of 1 trials. " A responder group The drugs used in multicrossover n of 1 trials must be easy to present to the patient blind. As both treatments are tested in one patient over a rather short time they must be similar in appearance, taste, smell, and consistency and without side effects. A prompt onset and offset of action is an advantage because it shortens each treatment period, allows more periods, and thereby comparisons, and reduces the length of the trial.2 Statistics in single subject trials
The statistical principles for n of 1 trials are analogous to those for group trials, but there are some important distinctions." The experimental unit in a group trial is the randomly selected subject whereas the equivalent unit in a single subject trial is the randomly allocated treatment period. The number of treatment periods has to be restricted to limit the duration ofthe trial. The corresponding low "sample size" makes n of 1 trials apt to overlook a difference in response (type II error). It is, however, fair to compare this risk with the opposite risk offalsely claiming a beneficial effect of the treatment (type I error) when the trial and error approach is used. Under the null hypothesis of no treatment effect the probability of such a conclusion is 50% or even higher ifthe regression and placebo effect is considered. '3 In conclusion, the single subject trial bridges the gap between research and clinical practice. It may provide new insight into vaguely defined conditions, improve therapeutic decisions, strengthen the doctor-patient relationship, and create a more critical attitude towards drug treatment both among patients and doctors.
